使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Gitanjali Ogawa - Head of Investor Relations
Gitanjali Ogawa - Head of Investor Relations
Good afternoon. I am Gita Jain, Head of Investor Relations, and I want to thank you for joining us today for Definium Therapeutics second quarter 2026 financial results and recent highlights conference call. All participants are in listen-only mode. This webcast is live on the investors section of Definium's webcast at definiumtx.com, and a replay will be available after the webcast.
各位下午好。我是Gita Jain,投資人關係主管,感謝各位今天參加Definium Therapeutics 2026年第二季財務業績與近期重點更新電話會議。所有與會者目前皆為僅收聽模式。本次網路直播可於definiumtx.com之Definium投資人專區收看,並將於直播結束後提供重播。
Leading the call today will be Rob Barrow, our Chief Executive Officer, who is joined by Dr. Dan Karlin, our Chief Medical Officer; Brandi Roberts, our Chief Financial Officer; and Matt Wiley, our Chief Commercial Officer.
今天的電話會議將由我們的執行長Rob Barrow主持,並由我們的醫務長Dan Karlin醫師、財務長Brandi Roberts,以及商務長Matt Wiley一同參與。
During today's call, we will be making certain forward-looking statements, including without limitation, statements about the potential safety, efficacy, and regulatory, and clinical progress of our product candidates, our anticipated cash runway, and our future expectations, plans, partnerships, and prospects. These statements are subject to various risks such as changes in market conditions and difficulties associated with research and development and regulatory approval processes. These and other risk factors are described in the filings made with the SEC and the applicable Canadian securities regulators, including our annual report on Form 10-K and Form 10-Q filed today.
在今天的電話會議中,我們將發表若干前瞻性陳述,包括但不限於:關於我們產品候選藥物之潛在安全性、有效性、監管與臨床進展的陳述;我們預期的現金可支應期間;以及我們對未來的預期、計畫、合作夥伴關係與前景。這些陳述受多項風險影響,例如市場狀況變化,以及研發與監管核准流程相關之困難。上述及其他風險因素已載於我們向美國證券交易委員會(SEC)及適用之加拿大證券監理機關所提交的文件中,包括我們的Form 10-K年度報告以及今日提交的Form 10-Q。
Forward-looking statements are based on the assumptions, opinions, and estimates of management at the date the statements are made, including the non-occurrence of the risks and uncertainties that are described in the filings made with the SEC and the applicable Canadian securities regulators or other significant events occurring outside of Definium's normal course of business. You are cautioned not to place undue reliance on these forward-looking statements, which are made as of today, August 6, 2026. Definium disclaims any obligation to update such statements, even if management's views change except as required by law.
前瞻性陳述係基於管理層於陳述作成日之假設、觀點與估計,包括:未發生我們向SEC及適用之加拿大證券監理機關所提交文件中所述之風險與不確定性,或未發生其他超出Definium正常營運範圍之重大事件。敬請注意勿過度依賴本等前瞻性陳述;本等陳述係截至今日(2026年8月6日)作成。除法律另有規定外,即使管理層觀點改變,Definium亦不承擔更新該等陳述之任何義務。
As announced in our earnings release, we anticipate presenting top-line results from Voyage, our first Phase III study of DT120 ODT and generalized anxiety disorder, or GAD, during the week of August 10, 2026. As such, we will not be holding a Q&A session at the conclusion of today's prepared remarks.
如我們在財報新聞稿中所宣布,我們預計於2026年8月10日當週公布Voyage研究的主要(top-line)結果;Voyage為我們針對DT120 ODT與廣泛性焦慮症(generalized anxiety disorder,簡稱GAD)的第一項第三期(Phase III)研究。因此,我們將不會在今天的事先準備發言結束後進行問答(Q&A)環節。
With that, let me turn the call over to Rob.
接下來,我把電話會議交給Rob。
Robert Barrow - Chief Executive Officer, Director
Robert Barrow - Chief Executive Officer, Director
Thank you, Gita, and thank you everyone for joining us today. Psychiatry has waited decades for therapies capable of fundamentally changing outcomes for patients. We believe that future is now coming into view. The unmet need has never been greater, and there is growing recognition that patients deserve treatments capable of delivering transformational outcomes.
謝謝你,Gita,也謝謝各位今天加入我們。精神醫學領域已等待數十年,期盼能有可從根本改變患者治療結果的療法。我們相信,那個未來如今正逐漸清晰可見。未被滿足的醫療需求從未如此迫切,且越來越多人認同患者值得擁有能帶來變革性療效的治療。
We are proud that Definium is leading the way in defining this next chapter, delivering pivotal evidence on DT120 ODT in pursuit of a best-in-class profile, targeting some of psychiatry's largest and most underserved indications.
我們很自豪Definium正引領方向,定義下一個篇章;我們正就DT120 ODT提供關鍵性(pivotal)證據,力求達到同類最佳(best-in-class)的特性,並鎖定精神醫學中規模最大且服務最不足的一些適應症。
First half of this year marked a key period of inflection and growth for our organization. In June, we reported positive top-line results from eMERGE, our first Phase III study of DT120 ODT in major depressive disorder, or MDD. These results establish a new benchmark in the field, having demonstrated what we believe to be the largest treatment effect ever reported in a Phase III MDD study.
今年上半年是我們組織的關鍵轉折與成長期。6月,我們公布eMERGE研究的正向主要結果;eMERGE為我們針對DT120 ODT與重度憂鬱症(major depressive disorder,簡稱MDD)的第一項第三期研究。這些結果為該領域建立了新的基準,因為其展現了我們認為在第三期MDD研究中迄今所報告的最大治療效果。
Taken together, the rapid and durable efficacy and favorable tolerability that we have consistently observed throughout the DT120 development program strengthens our confidence that DT120 has the potential to meaningfully change the treatment paradigm for patients living with anxiety, depression, and post-traumatic stress disorder or PTSD.
綜合而言,我們在DT120開發計畫中一貫觀察到的快速且持久的療效,以及良好的耐受性,進一步強化我們的信心:DT120有潛力實質改變焦慮、憂鬱與創傷後壓力症候群(post-traumatic stress disorder,簡稱PTSD)患者的治療典範。
We continue to make major progress across our pipeline, having completed enrollment in both Voyage and Panorama, our two Phase III studies in GAD; initiated enrollment in Ascend, our second Phase III study in MDD, from which we expect top-line data in 2027; and advanced preparations for Haven, our planned Phase III study in PTSD, which we expect to initiate in 2027.
我們在產品線上持續取得重大進展:已完成Voyage與Panorama兩項GAD第三期研究的受試者招募;已啟動Ascend(我們在MDD的第二項第三期研究)的收案,並預期於2027年取得主要數據;同時也推進Haven(我們規劃中的PTSD第三期研究)的前期準備,預計於2027年啟動。
Looking ahead, we are in what we believe is one of the most important periods in our company's evolution. Next week, we plan to share top-line results from Voyage and we expect to share top-line results from Panorama in September.
展望未來,我們正處於公司演進中我們認為最重要的時期之一。下週我們計畫分享Voyage的主要結果,並預期於9月分享Panorama的主要結果。
Given that there has not been a new drug approved for this highly prevalent burdensome disorder in almost 20 years, we believe there is an extraordinary opportunity to deliver a first and best-in-class treatment for GAD.
鑑於這個高盛行率且負擔沉重的疾病近20年來幾乎沒有新藥獲准,我們相信在GAD領域存在極為難得的機會,可望提供首創且同類最佳(first- and best-in-class)的治療。
In parallel to our clinical progress, we continue to efficiently advance toward a potential NDA submission for DT120 ODT. Throughout the development program, we have worked closely with FDA, maintaining a constructive dialogue that has shaped our program and aligned with expectations for the field. We believe the agency's recently finalized guidance closely reflects this alignment and the principles that have guided our regulatory strategy from the outset.
在推進臨床進展的同時,我們也持續以高效率朝DT120 ODT可能的NDA(新藥申請)遞交邁進。在整個開發計畫中,我們與FDA密切合作,維持建設性的對話,該對話塑造了我們的計畫,並與該領域的預期保持一致。我們相信,主管機關近期定稿的指引高度反映了這種一致性,以及自一開始即引導我們監管策略的原則。
We've also continued growing and strengthening our organization to deliver on the clinical, regulatory, and commercial milestones ahead. Over the course of the year, we have significantly expanded our commercial capabilities in preparation for the potential launch of DT120 ODT if approved, and we have strengthened our balance sheet with an upsized public offering that generated approximately $805 million in gross proceeds.
我們也持續擴充並強化組織,以達成接下來的臨床、監管與商業化里程碑。在今年期間,我們已大幅提升商業化能力,以因應DT120 ODT若獲核准之潛在上市;同時,我們透過擴大規模的公開發行強化資產負債表,該次發行帶來約8.05億美元的總募集資金(gross proceeds)。
With our strong financial position and operational momentum, we are well positioned to continue advancing our R&D programs while preparing for a launch of DT120 ODT that reflects both the scale of the commercial opportunity and more importantly, the magnitude of patient need. Our progress is a result of disciplined execution of our team and our commitment to delivering meaningful value for patients and shareholders.
憑藉我們強勁的財務狀況與營運動能,我們已具備良好條件,在持續推進研發計畫的同時,為DT120 ODT的上市做準備;該上市規劃將同時反映商業機會的規模,更重要的是反映患者需求的迫切程度。我們的進展來自團隊有紀律的執行,以及我們致力於為患者與股東創造具意義價值的承諾。
With that, I'll turn the call over to Dan to review our clinical programs in more detail.
接下來,我將把電話會議交給 Dan,由他更詳細地回顧我們的臨床計畫。
Daniel Karlin - Chief Medical Officer
Daniel Karlin - Chief Medical Officer
As Rob highlighted, our positive Phase III eMERGE results represent an important milestone, not only for the DT120 program, but for the field of psychiatry. As a psychiatrist, what is most exciting to me is the consistent profile of DT120 ODT we have seen across the development program.
如 Rob 所強調,我們正向的第三期 eMERGE 結果是一個重要里程碑,不僅對 DT120 計畫而言如此,對精神醫學領域亦然。身為精神科醫師,最令我振奮的是,我們在整個開發計畫中所看到的 DT120 ODT 一致性特徵。
Rapid onset of action, durable clinical benefit, and a favorable tolerability profile. We believe this combination has the potential to fundamentally change how anxiety, depression, and PTSD are treated. eMERGE enrolled 149 participants with moderate to severe MDD.
起效迅速、臨床效益持久,以及良好的耐受性特徵。我們相信,這樣的組合有潛力從根本上改變焦慮、憂鬱與 PTSD 的治療方式。eMERGE 共納入 149 名中度至重度 MDD 受試者。
The study population had a mean baseline Montgomery-Ã sberg Depression Rating Scale, or MADRS, score of 34.5, and approximately half of participants in the study had previously been failed by two or more antidepressant therapies.
研究族群的蒙哥馬利–Åsberg 憂鬱量表(Montgomery-Åsberg Depression Rating Scale,MADRS)基線平均分數為 34.5,且約有一半的受試者先前曾對兩種或以上的抗憂鬱治療反應失敗。
Background antidepressant and anxiolytic medications were discontinued before randomization and no psychotherapy was provided as a component of the study, allowing us to evaluate DT120 as a true monotherapy.
在隨機分派前已停用背景抗憂鬱與抗焦慮藥物,且研究中未將心理治療納入組成部分,使我們得以將 DT120 作為真正的單一療法進行評估。
The study met all of its primary and key secondary endpoints with highly statistically significant results across multiple clinically meaningful measures. DT120 demonstrated an [8.1-point] placebo-adjusted improvement on the MADRS at week six with a p-value of less than 0.0001, corresponding to an effect size of approximately 0.83 for the primary endpoint. To our knowledge, this represents the largest treatment effect ever reported in a Phase III trial in MDD.
本研究在所有主要與關鍵次要終點皆達成,且在多項具臨床意義的衡量指標上呈現高度統計顯著的結果。在第六週,DT120 在 MADRS 上顯示相較安慰劑校正後改善 [8.1 分],p 值小於 0.0001,對應主要終點的效應量約為 0.83。據我們所知,這是 MDD 第三期試驗中迄今報告過的最大治療效果。
Importantly, after a single dose of DT120 ODT, efficacy was evident as early as week one, remained statistically significant at every subsequent assessment and persisted through week 12. Beyond the primary outcome measure, we observed statistically significant improvements across all key secondary endpoints and a favorable tolerability profile.
重要的是,在單次給予 DT120 ODT 後,療效最早於第一週即已顯現,且在其後每次評估皆維持統計顯著,並持續至第 12 週。除主要結果指標外,我們亦觀察到所有關鍵次要終點皆有統計顯著改善,且耐受性特徵良好。
We are extremely encouraged by the eMERGE results and look forward to delivering pivotal data in GAD. GAD affects millions of patients worldwide, yet treatment options have not changed over the past two decades. With the available approved medications, many patients continue to experience inadequate symptom control, delayed onset of benefit, poor tolerability, and the burden of taking chronic daily pharmacotherapy.
我們對 eMERGE 的結果深受鼓舞,並期待在 GAD 方面提供關鍵性數據。GAD 影響全球數以百萬計的患者,然而過去二十年治療選項幾乎未有改變。在現有已核准藥物下,許多患者仍面臨症狀控制不足、起效延遲、耐受性不佳,以及需長期每日用藥的負擔。
Our objective with DT120 is fundamentally different. Rapid and durable clinical benefit from a single treatment session that can be reinforced with intermittent retreatment as needed based on patient presentation.
我們對 DT120 的目標在本質上不同。透過單次治療療程即可帶來快速且持久的臨床效益,並可依患者表現於需要時以間歇性再治療加以強化。
Our confidence in the DT120 program is grounded in the consistency of the evidence generated to date. In our Phase II GAD study, DT120 demonstrated rapidly, clinically meaningful improvements that were sustained through 12 weeks following treatment.
我們對 DT120 計畫的信心,建立在迄今所產生證據的一致性之上。在我們的第二期 GAD 研究中,DT120 展現快速且具臨床意義的改善,並在治療後持續至 12 週。
Voyage and Panorama are intended to rigorously confirm those findings in two independent well-controlled pivotal studies. Voyage and Panorama were initially designed with approximately 90% [power] to detect a [5-point] placebo adjusted treatment effect.
Voyage 與 Panorama 旨在透過兩項獨立、設計嚴謹且對照良好的關鍵性研究,嚴格驗證上述發現。Voyage 與 Panorama 最初設計為具約 90% 的[檢定力],以偵測相較安慰劑校正後 [5 分] 的治療效果。
Based on the protocol specified blinded sample size re-estimation, which assessed variance of the primary outcome measure and dropout rates, both studies would be expected to have greater than 99% power to detect a five-point placebo-adjusted treatment effect.
根據方案所規定的盲態樣本數重新估算(評估主要結果指標的變異數與退組率),兩項研究預期皆將具備超過 99% 的檢定力,以偵測相較安慰劑校正後 5 分的治療效果。
Notably, while the studies were powered to detect a 5-point difference, we believe a placebo-adjusted improvement of 4 points or greater at week 12 would compare favorably with the currently available treatments and other investigational products in development.
值得注意的是,雖然研究的檢定力設定為偵測 5 分差異,但我們認為在第 12 週相較安慰劑校正後改善達 4 分或以上,將可與目前可用治療及其他開發中的研究性產品相比具有競爭力。
Beyond DT-120, we continue to advance DT-402 in autism spectrum disorder or ASD. We believe this program represents an important long-term opportunity given the significant unmet need and the absence of FDA-approved therapies that directly address the core social communication challenges associated with ASD. Across the development programs, we are incredibly excited by the results we've been able to produce to date and the ones we expect to share in the near term.
除 DT-120 外,我們也持續推進 DT-402 於自閉症譜系障礙(autism spectrum disorder,ASD)的開發。鑑於龐大的未被滿足需求,以及缺乏能直接處理 ASD 核心社交溝通挑戰的 FDA 核准療法,我們相信此計畫代表一項重要的長期機會。在各項開發計畫中,我們對迄今所取得的成果,以及預期在近期分享的結果,都感到非常振奮。
Now I'll turn the call over to Matt to comment on our ongoing commercial preparations as we seek to translate clinical excellence into commercial success.
現在我將把電話會議交給 Matt,請他談談我們在持續進行的商業化準備,因為我們正致力於將臨床卓越轉化為商業成功。
Matthew Wiley - Chief Commercial Officer
Matthew Wiley - Chief Commercial Officer
Thanks, Dan. I'm excited to spend a few minutes sharing more about our accelerating commercial momentum for DT120 which has been further strengthened by the positive Phase III emerge results. These results have given us greater confidence in DT120's potential to deliver meaningful, rapid, and durable benefit for patients with MDD and GAD.
謝謝你,Dan。我很高興用幾分鐘分享我們在 DT120 商業動能加速方面的更多進展,而這股動能也因正向的第三期 eMERGE 結果而進一步強化。這些結果讓我們更有信心,相信 DT120 有潛力為 MDD 與 GAD 患者帶來具意義、快速且持久的效益。
In our market research, both patient populations have clearly expressed dissatisfaction with current treatment options and have responded positively to the DT120 product profile. On the heels of eMERGE, we are moving with urgency to further build a fully integrated commercial apparatus designed to deliver on the full potential of DT120 adoption if approved.
在我們的市場研究中,兩個患者族群都清楚表達對現行治療選項的不滿,並對 DT120 的產品特徵做出正面回應。在 eMERGE 之後,我們正以更高的急迫感推進,進一步建構一套完整整合的商業化體系,以在若獲核准時充分釋放 DT120 採用的全部潛力。
A strong recent example of this execution is our Wired for Worry campaign launched in July. This campaign is designed to raise awareness of the persistent burden and underlying neurobiology of GAD, highlight key unmet needs, and equip clinicians to better identify patients who may benefit from new treatment options. Early feedback has been highly positive, and the campaign is already driving meaningful engagement as we near the upcoming GAD data readouts.
近期執行力的一個強力例證,是我們於 7 月推出的「Wired for Worry」宣導活動。此活動旨在提升對 GAD 持續性負擔及其潛在神經生物學的認識,凸顯關鍵未被滿足需求,並協助臨床醫師更好地辨識可能受益於新治療選項的患者。早期回饋非常正面,且在我們接近即將公布的 GAD 數據讀出之際,該活動已在推動具意義的互動參與。
At the same time, we are rapidly expanding our commercial team and building our critical operational capabilities. We are hiring and onboarding key talent across marketing, market access, sales, and commercial operations while executing on essential launch activities, including promotional message development, payer value narratives, and engagement, distribution model design, and detailed deployment planning. These efforts are advancing in parallel with the build-out of our centralized patient support services, reimbursement pathways, field operational readiness, and HCP engagement initiatives, all aligned to ensure a strong, seamless launch.
同時,我們正快速擴編商業團隊並建立關鍵營運能力。我們正在行銷、市場准入、銷售與商業營運等領域招募並到職關鍵人才,同時推進必要的上市準備工作,包括促銷訊息開發、支付方價值論述與互動、通路/配送模式設計,以及細緻的部署規劃。這些工作也與我們集中式病患支持服務、給付/報銷途徑、外勤營運就緒度,以及醫療照護專業人員(HCP)互動倡議的建置同步推進,並彼此對齊,以確保強勁且無縫的上市。
Throughout this process, we are focused on making the patient and provider experience exceptional, leveraging the same unique insights and discipline execution that have defined our R&D approach. We are highly confident in the clinical profile of DT120, our go-to-market strategy, and our commercial readiness.
在整個過程中,我們專注於打造卓越的病患與醫療提供者體驗,並運用與我們研發(R&D)方法一脈相承的獨特洞察與嚴謹的執行力。我們對 DT120 的臨床特徵、我們的上市策略,以及我們的商業化就緒程度都抱持高度信心。
We believe our recent MDD and upcoming GAD pivotal data, combined with the momentum from market conditioning efforts and our accelerated infrastructure build, positioned Definium exceptionally well for a successful launch and to set the standard for this new and exciting treatment modality.
我們相信,近期的 MDD 以及即將公布的 GAD 關鍵性數據,加上市場教育(market conditioning)工作的動能與我們加速建置的基礎設施,使 Definium 具備極佳條件可成功上市,並為這項嶄新且令人振奮的治療模式樹立標準。
With that, I'll turn it over to Brandy for our financial results.
接下來,我把時間交給 Brandy,請她說明我們的財務結果。
Brandi Roberts - Chief Financial Officer
Brandi Roberts - Chief Financial Officer
Thank you, Matt. Before reviewing our financial results, I'd like to briefly discuss the financing we completed during the quarter and how it positions Definium for the years ahead. In June, we completed an upsized underwritten public offering that generated approximately $758 million in net proceeds. We were pleased by the strong participation from both existing and new investors, and we believe the successful financing reflects growing confidence in DT120, our broader pipeline, and our long-term vision for the company.
謝謝你,Matt。在回顧我們的財務結果之前,我想先簡要說明我們在本季完成的融資,以及它如何讓 Definium 在未來數年更具優勢。6 月,我們完成一項擴大規模的承銷公開發行,淨募資約 7.58 億美元。我們很高興看到既有與新投資人皆踴躍參與,並且我們相信,這次成功的融資反映市場對 DT120、我們更廣泛的產品線,以及公司長期願景的信心正在提升。
Importantly, this financing significantly strengthened our balance sheet and we ended the quarter with approximately $1.1 billion in cash, cash equivalents, and investments. Based on our current operating plans, we believe this capital is sufficient to fund planned operations into 2030. The strong financial position provides the resources to execute our strategy while maintaining financial flexibility.
重要的是,這次融資大幅強化了我們的資產負債表,我們在季末持有約 11 億美元的現金、約當現金及投資。依據我們目前的營運計畫,我們認為這些資金足以支應已規劃的營運至 2030 年。強健的財務狀況提供我們執行策略所需資源,同時維持財務彈性。
If DT120 is approved, our goal is to ensure it reaches the patients who need it and the providers who have long been seeking better treatment options. We continue to make significant investments in market access, medical affairs, provider education, patient support programs, and other critical launch activities while simultaneously advancing our pivotal DT120 programs, DT402 program, and broader R&D pipeline. We believe this positions us to maximize the opportunity for DT120 and continue building long-term value across the organization.
若 DT120 獲得核准,我們的目標是確保它能觸及有需要的病患,以及長期以來一直尋求更佳治療選項的醫療提供者。我們持續在市場准入、醫學事務、醫療提供者教育、病患支持計畫及其他關鍵上市活動上進行重大投資,同時推進 DT120 關鍵性計畫、DT402 計畫,以及更廣泛的研發產品線。我們相信,這使我們能最大化 DT120 的機會,並持續在整個組織中建立長期價值。
I'll now turn to our financial results for the second quarter of 2026, which are detailed in the earnings press release we issued this afternoon. Research and development expenses were $48.7 million for the second quarter of 2026 compared to $29.8 million in the prior year period. The increase was primarily driven by higher DT120 program expenses and additional personnel costs as we expanded our R&D capabilities.
接下來我將說明 2026 年第二季的財務結果,相關內容已詳列於我們今天下午發布的財報新聞稿中。2026 年第二季研發費用為 4,870 萬美元,去年同期為 2,980 萬美元。增加主要來自 DT120 計畫費用提高,以及我們擴充研發能力所帶來的新增人員成本。
General and administrative expenses were $26.4 million compared to $11.1 million in the second quarter of 2025. The increase was primarily due to higher stock-based compensation, corporate and government affairs activities, personnel-related costs, and commercial readiness investments.
一般及行政費用為 2,640 萬美元,2025 年第二季為 1,110 萬美元。增加主要由於較高的股份基礎給付、公司與政府事務活動、人員相關成本,以及商業化就緒投資。
The year-over-year increase in both R&D and G&A expenses reflects continued investment across our clinical development programs, commercial readiness activities, and broader organizational capabilities as we prepare for potential commercialization. Overall, our operating expenses for the quarter were in line with our internal expectations.
研發與一般及行政費用的年增,反映我們在臨床開發計畫、商業化就緒活動,以及更廣泛的組織能力上持續投入,以因應潛在的商業化準備。整體而言,本季營運費用符合我們內部預期。
Net loss for the second quarter of 2026 was $159 million compared to $42.7 million for the second quarter of 2025. As a reminder, net loss can be significantly impacted by changes in the fair value of our USD financing warrants, which are marked to market each quarter.
2026 年第二季淨損為 1.59 億美元,2025 年第二季為 4,270 萬美元。提醒各位,淨損可能會受到我們以美元計價之融資認股權證公允價值變動的顯著影響,該等權證每季按市價評價(mark-to-market)。
During the second quarter, the change in fair value of these warrants resulted in an $86.2 million non-cash expense, primarily reflecting the increase in our share price from $18.90 at March 31, 2026, took $47.04 at June 30, 2026.
第二季期間,這些權證的公允價值變動造成 8,620 萬美元的非現金費用,主要反映我們股價自 2026 年 3 月 31 日的 18.90 美元,上升至 2026 年 6 月 30 日的 47.04 美元。
As we look ahead, our focus remains on disciplined execution and thoughtful capital allocation. We have an important period ahead of us, and we believe our strong financial position gives us the flexibility to invest in our key priorities while continuing to create long-term value for both patients and shareholders.
展望未來,我們的重點仍是有紀律的執行與審慎的資本配置。接下來是一段關鍵時期,我們相信強健的財務狀況讓我們能在持續為病患與股東創造長期價值的同時,保有彈性以投資於核心優先事項。
With that, I'll turn the call back to Rob.
接下來,我把電話會議交回給 Rob。
Robert Barrow - Chief Executive Officer, Director
Robert Barrow - Chief Executive Officer, Director
Thanks, Brandi. I want to extend my sincere thanks to the entire Definium team for your tireless work to make our successes possible. The progress we have made reflects years of scientific rigor, disciplined execution, and unwavering commitment to developing therapies that have the potential to meaningfully improve the lives of patients living with anxiety, depression, PTSD, and other serious psychiatric disorders.
謝謝你,Brandi。我想向整個 Definium 團隊致上誠摯謝意,感謝各位不懈的努力讓我們得以取得這些成果。我們所取得的進展,反映多年來的科學嚴謹、紀律執行,以及對開發有潛力實質改善焦慮、憂鬱、PTSD 與其他嚴重精神疾病患者生活之療法的堅定承諾。
As I said at the outset of today's call, we believe a new chapter for psychiatric care is on the horizon. We could not be more energized or excited to play a leading role in seeking to make that promise a reality.
如同我在今天電話會議一開始所說,我們相信精神醫療照護的新篇章已近在眼前。我們充滿動能與期待,並很高興能在推動這項承諾成真方面扮演領導角色。
In pursuit of that mission, we remain highly focused on executing against the clinical, regulatory, and commercial objectives ahead of us. As we expect to share top-line results from Voyage next week, we will not be holding a question-and-answer session following today's call.
為了達成這項使命,我們仍高度聚焦於推進眼前的臨床、法規與商業目標。由於我們預期將於下週分享 Voyage 的主要結果(top-line results),因此今天的電話會議結束後將不進行問答環節。
We look forward to discussing the results in greater detail after the data release, and thank you all for your continued support of Definium. That concludes today's session. You may now disconnect.
我們期待在數據發布後更深入討論結果,也感謝各位持續支持 Definium。今天的會議到此結束。您現在可以掛線。